Pamlectabart tismanitin

Ladenburg, Germany, 6 November 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage developer of innovative Antibody Drug Conjugates (ADCs), today announces that new clinical data on its lead Amanitin-based ADC candidate, HDP-101, will be presented at the 66th American Society of Hematology (ASH) Annual Meeting, taking place from 7-10 December 2024 in San Diego, California, USA. Robert Z. Orlowski, MD, PhD, (Ad Interim) Director of Myeloma and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics, University of Texas, Houston, Texas, and principal investigator at MD Anderson Cancer Center, Houston, Texas, USA, will report the latest developments from the ongoing Phase I/IIa study of HDP-101 for the treatment of relapsed or refractory multiple myeloma. Currently advancing in its sixth cohort, the study has shown encouraging results, including complete remission in one patient from the fifth cohort who had been previously treated multiple times and had received several courses of HDP-101. In addition, several patients showed promising biological activity and objective improvements, underscoring the potential of HDP-101 as a treatment option for patients with this disease. 66th American Society of Hematology (ASH) Annual Meeting Publication number: Publication number: #3381 #3381 Session: Session: 654. Multiple Myeloma: Pharmacologic Therapies: Poster II 654. Multiple Myeloma: Pharmacologic Therapies: Poster II Presentation title: Presentation title: The Anti-BCMA Antibody-Drug Conjugate HDP-101 with a Novel Amanitin Payload Shows Promising Initial First in Human Results in Relapsed Multiple Myeloma The Anti-BCMA Antibody-Drug Conjugate HDP-101 with a Novel Amanitin Payload Shows Promising Initial First in Human Results in Relapsed Multiple Myeloma Time & location: Time & location: 8 December, 6:00 – 8:00 pm PST, Hall G–H 8 December, 6:00 – 8:00 pm PST, Hall G–H Presenter: Presenter: Robert Z. Orlowski, MD, PhD, MD Anderson Cancer Center, Houston, Texas, USA Robert Z. Orlowski, MD, PhD, MD Anderson Cancer Center, Houston, Texas, USA In October, Robert Z. Orlowski, MD, PhD, along with Heidelberg Pharma's Chief Medical Officer, András Strassz, and another Key Opinion Leader (KOL) in the field of Myeloma, discussed the progress of the dose escalation study of HDP-101 during a R&D webinar. Robert Z. Orlowski commented, “I would say that this should be considered a great drug for all relapsed or refractory myelomas.” The recording of the R&D webinar can be found here: Virtual KOL Event on Multiple Myeloma and Updated Clinical Data from the IMS Oral Presentation of HDP-101, an Anti-BCMA ADC

Ladenburg, Germany, 24 October 2024 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage developer of innovative Antibody Drug Conjugates (ADCs), announces it will present its ADC candidates and ADC technology platforms at leading scientific and financial conferences throughout November. The Company’s most advanced Amanitin-based ADC product candidate, HDP-101, is currently in a Phase I/IIa trial for the treatment of relapsed or refractory multiple myeloma. In late September, Heidelberg Pharma presented clinical data from the fifth patient cohort, demonstrating a case of complete remission in a patient who had been treated multiple times. This patient showed a partial response after the second treatment cycle, with a complete remission observed after 11 cycles. In addition, several patients exhibited promising biological activity and objective improvements, underscoring the potential of HDP-101 as a treatment option for patients with this disease. HDP-201, Heidelberg Pharma’s first Exatecan-based ADC candidate, is a topoisomerase I inhibitor that has proven success in cancer therapy and is already used in two approved ADCs. Its distinct mode of action from Amanitin broadens the Company’s portfolio of active ingredients. HDP-201 targets guanylyl cyclase-C (GCC), a receptor expressed on the surface of intestinal cells and cancer cells in various gastrointestinal tumors. Preclinical data suggest that the tolerability and efficacy of HDP-201 is at least on a par with existing, approved Exatecan-based ADCs. Following extensive preclinical testing, the final development candidate for HDP-201 was determined in recent weeks, with colorectal cancer identified as the target indication for its clinical development. World ADC San Diego 2024 Date & location: 4 – 7 November 2024 San Diego, California, USA Workshop: 2nd Biomarker & Patient Selection Day Date: 4 November, 10:30 am PST Title of presentation: Leveraging 17p Deletion as a Biomarker & Patient Selection Tool for Amanitin Payload ADCs Presenter: Anikó Pálfi, Director Biochemistry & Cell Biology Stream: Discovery Chemistry Date: 6 November, 2:00 pm PST Title of presentation: HDP-201, a Multimeric Linker-Exatecan-based ADC as Novel Therapeutic Modality for Treatment of Solid Tumors Presenter: Professor Andreas Pahl, CEO Plenary: BCMA Breakdown: Exploring Case Studies of ADC Development for Targets Without an Approved Therapy Date: 6 November, 4:00 pm PST Title of presentation: ATACs: A New Payload Provides New Options for Cancer Therapy Presenter: Dr. Torsten Hechler, Senior Vice President ADC Research Deutsches Eigenkapitalforum Date & location: 25 – 27 November 2024, Frankfurt, Germany Panel: Company Presentations (Room Zurich) Date: 26 November, 11:15 am MEZ Title of presentation: Leader in Next Generation ADC Payloads Presenter: Walter Miller, Chief Financial Officer Walter Miller will be available for one-on-one meetings, which can be arranged via the online conference system.